Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Author:

Kiyota Naomi1,Robinson Bruce2,Shah Manisha3,Hoff Ana O.4,Taylor Matthew H.5,Li Di6,Dutcus Corina E.6,Lee Eun Kyung7,Kim Sung-Bae8,Tahara Makoto9

Affiliation:

1. Department of Medical Oncology and Hematology, Kobe University Hospital and Kobe University Hospital Cancer Center, Kobe, Japan.

2. Kolling Institute of Medical Research, University of Sydney, New South Wales, Australia.

3. Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

4. Department of Endocrinology, Endocrine Oncology Unit, Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.

5. Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

6. Eisai, Inc., Woodcliff Lake, New Jersey.

7. Center for Thyroid Cancer, National Cancer Center, Goyang, South Korea.

8. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

9. Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3